AFFY Affymax Inc.
- 1.3 P/E
- 94.98 P/S
- 0.77 P/B
- 0.082 EPS
- 0 / 0% Dividend
- 488,038.00 Avg. Vol.
- 37.78M Shares
- 5.1M Market Cap.
Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...
Wall Street Journal - Jul 31, 2014
Seeking Alpha (registration) - 17 hours ago
Wall Street Journal - Aug 13, 2014
InvestorIdeas.com (press release) - Aug 14, 2014
Reuters Key Development - Jun 24, 2014
Reuters Key Development - Jun 13, 2014
Reuters Key Development - Jun 7, 2013
Reuters Key Development - Apr 26, 2013
Reuters Key Development - Apr 13, 2013
Reuters Key Development - Mar 25, 2013